Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target

被引：23
|
作者：
Yang, Jiayin [1 ,2 ]
Liao, Xiaohong [3 ]
Yu, Jerry [4 ]
Zhou, Ping [1 ]
机构：
[1] Fudan Univ, Sch Basic Med Sci, Dept Physiol & Pathophysiol, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China
[2] Dent Dis Prevent & Treatment Ctr Jiading Dist, Shanghai 201899, Peoples R China
[3] Ganzhou Peoples Hosp, Dept Oncol, Ganzhou 341000, Peoples R China
[4] Univ Louisville, Dept Med, Louisville, KY 40292 USA
来源：
CURRENT MEDICINAL CHEMISTRY | 2018年 / 25卷 / 19期
关键词：
CD73; ecto-5 '-nucleotidase; cancer; immunity; inflammation; disease; ENDOTHELIAL BARRIER FUNCTION; VASCULAR ADHESION PROTEIN-2; MALIGNANT EPITHELIAL-CELLS; ECTO-5'-NUCLEOTIDASE CD73; EXTRACELLULAR ADENOSINE; HIGH EXPRESSION; PROTECTIVE ROLE; IFN-BETA; T-CELLS; 5'-ADENOSINE MONOPHOSPHATE;
D O I：
10.2174/0929867325666180117101114
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
CD73, also known as ecto-5'-nucleotidase (eN, NT5E, EC3.13.5), is the rate limiting enzyme for adenosine generation and is expressed on multiple cells. Its expression is significantly influenced by hypoxia and inflammatory factors. During inflammation, CD73 protects endothelial barrier function and inhibits leukocyte trafficking. CD73 also promotes M2 macrophages (anti-inflammatory phenotype). In addition, CD73 is expressed on Treg cells and mediates immune suppression through adenosine. CD73 serves as an essential regulator for the immunity and inflammation. Its expression is related to many diseases, such as autoimmune diseases, ischemia-reperfusion injuries, arterial calcifications, and atherosclerosis. CD73 is overexpressed in many cancers. Its expression is positively associated with tumor growth, metastasis, angiogenesis, poor prognosis and resistance to chemotherapy. Thus, CD73 may be used for prognostic indicator and therapeutic target in diseases such as cancers.
引用
收藏
页码：2260 / 2271
页数：12
相关论文
共 50 条
  • [41] Regulatory role of CD39 and CD73 in tumor immunity
    Kaplinsky, Nicole
    Williams, Kada
    Watkins, Dean
    Adams, Molly
    Stanbery, Laura
    Nemunaitis, John
    FUTURE ONCOLOGY, 2024, 20 (19) : 1367 - 1380
  • [42] Role of CD73 and extracellular adenosine in disease (vol 7, pg 367, 2011)
    Tapper, Elliot
    Schmelzle, Moritz
    Eltzschig, Holger K.
    Robson, Simon C.
    PURINERGIC SIGNALLING, 2012, 8 (02) : 339 - 339
  • [43] CD73 as a Novel Prognostic Biomarker for Human Colorectal Cancer Reply
    Wu, Xian-Rui
    He, Xiao-Sheng
    Chen, Yu-Feng
    Wu, Xiao-Jian
    Lan, Ping
    JOURNAL OF SURGICAL ONCOLOGY, 2012, 106 (07) : 920 - 920
  • [44] Significance of Novel Immunotherapy Target CD73 in Primary Colorectal Adenocarcinoma
    Katkhuda, Riham
    Verma, Anuj
    Agarwal, Atin
    Neishaboori, Nastaran
    Wistuba, Ignacio
    Overman, Michael
    Kopetz, Scott
    Jiang, Zhi-Qin
    Mino, Barbara
    Soto, Luisa Solis
    Maru, Dipen
    MODERN PATHOLOGY, 2019, 32
  • [45] Significance of Novel Immunotherapy Target CD73 in Primary Colorectal Adenocarcinoma
    Katkhuda, Riham
    Verma, Anuj
    Agarwal, Atin
    Neishaboori, Nastaran
    Wistuba, Ignacio
    Overman, Michael
    Kopetz, Scott
    Jiang, Zhi-Qin
    Mino, Barbara
    Soto, Luisa Solis
    Maru, Dipen
    LABORATORY INVESTIGATION, 2019, 99
  • [46] Characterisation of novel CD73 antibodies as a therapeutic method of adenosine regulation
    Gernon, Grainne
    Grooby, Suzanne
    Tonkin, Louise
    Bitterwolf, Anja-Christina
    Stewart, Lorna
    Deken, Marcel
    Shah, Pritom
    Ewings, Katherine
    Johnson, Zoe
    CANCER RESEARCH, 2020, 80 (16)
  • [47] Role of CD73 in renal sympathetic neurotransmission in the mouse kidney
    Jackson, Edwin K.
    Cheng, Dongmei
    Mi, Zaichuan
    Verrier, Jonathan D.
    Janesko-Feldman, Keri
    Kochanek, Patrick M.
    PHYSIOLOGICAL REPORTS, 2013, 1 (03):
  • [48] Potential role of CD73 in basophil non-reactivity
    Sonder, S.
    Alpan, O.
    Plassmeyer, M.
    Loizou, D.
    Kim, T.
    ALLERGY, 2019, 74 : 599 - 599
  • [49] Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target
    Le, Xiuning
    Negrao, Marcelo, V
    Reuben, Alexandre
    Federico, Lorenzo
    Diao, Lixia
    McGrail, Daniel
    Nilsson, Monique
    Robichaux, Jacqulyne
    Munoz, Irene Guijarro
    Patel, Sonia
    Elamin, Yasir
    Fan, You-Hong
    Lee, Won-Chul
    Parra, Edwin
    Soto, Luisa Maren Solis
    Chen, Runzhe
    Li, Jun
    Karpinets, Tatiana
    Khairullah, Roohussaba
    Kadara, Humam
    Behrens, Carmen
    Sepesi, Boris
    Wang, Ruiping
    Zhu, Mingrui
    Wang, Linghua
    Vaporciyan, Ara
    Roth, Jack
    Swisher, Stephen
    Haymaker, Cara
    Zhang, Jianhua
    Wang, Jing
    Wong, Kwok-Kin
    Byers, Lauren A.
    Bernatchez, Chantale
    Zhang, Jianjun
    Wistuba, Ignacio I.
    Gibbons, Don L.
    Akbay, Esra A.
    Heymach, John, V
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : 583 - 600
  • [50] Prognostic significance of CD73 expression in localized renal cell carcinoma (RCC).
    Tripathi, Abhishek
    Xie, Wanling
    Flaifel, Abdallah
    Steinharter, John A.
    Gatof, Emily Stern
    Jennings, Rebecca B.
    Bouchard, Gabrielle
    Fleischer, Justin
    Chanza, Nieves M.
    Gray, Connor
    Mantia, Charlene
    Wei, Xiao X.
    Giannakis, Marios
    McGregor, Bradley Alexander
    Choueiri, Toni K.
    McDermott, David F.
    Signoretti, Sabina
    Harshman, Lauren Christine
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345